Story perspectives

Experimental Drug Elraglusib Doubles Survival in Pancreatic Cancer

4/18/2026

Summary

Story summary

A Nature Medicine study reports that elraglusib (an experimental cancer drug) added to standard chemotherapy doubled one-year survival rates in pancreatic cancer.
In a phase 2 trial of 286 participants, elraglusib plus chemotherapy produced a 10.1-month median survival versus 7.2 months with chemotherapy alone.
Elraglusib targets the tumor microenvironment to boost efficacy.
Side effects were manageable.
A larger phase 3 trial will confirm results and assess elraglusib in other cancers.

1 of 1

Story summary

A Nature Medicine study reports that elraglusib (an experimental cancer drug) added to standard chemotherapy doubled one-year survival rates in pancreatic cancer.
In a phase 2 trial of 286 participants, elraglusib plus chemotherapy produced a 10.1-month median survival versus 7.2 months with chemotherapy alone.
Elraglusib targets the tumor microenvironment to boost efficacy.
Side effects were manageable.
A larger phase 3 trial will confirm results and assess elraglusib in other cancers.